NEW YORK and LONDON, April 18, 2019 /PRNewswire/ — TAU BIO-LOGIC CORP. announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3). TAU BIO-LOGIC is developing TBL-100 for the treatment of Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP). The humanized antibody has an affinity for tauC3 of 13pM (about 100-fold higher than most marketed therapeutic antibodies have for their targets) and a specificity that is 1000-fold greater than for full length tau (FLT). The high affinity and specificity of the antibody are expected to translate into improved efficacy and safety compared to other tau antibodies currently in development. TauC3 exists in lower abundance than FLT or N-terminally truncated tau but exerts disproportionately large pathological effects. This is due to tauC3 having the highest propensity to aggregate among all forms of tau and its also having the ability to recruit normal tau and nucleate pathological tau conformations. In AD, tauC3 is formed early in the disease course and levels correlate with cognitive decline. TauC3 causes intracellular neurotoxicity and is also believed to be the major driver of tau propagation. A study conducted by Professor Bradley Hyman at Harvard Medical School demonstrated TBL-100’s potential to block tau propagation in the AD brain (Nicholls et al., 2017; PLoS ONE 12(5): e0177914). In PSP, tauC3 production and activity have been linked to a single polynuclear polymorphism (SNP) at rs1768208, a significant risk factor for the disease. Thus, TBL-100 could be beneficial for this condition as well.
The humanization of TBL-100 was conducted by LifeArc under a risk sharing agreement with TAU BIO-LOGIC, with terms that would see LifeArc receive a small royalty on future drug sales. “We are delighted to have contributed to the development of TBL-100, ” said Dr Justin Bryans, head of LifeArc’s Centre for Therapeutic Discovery. “The collaboration has produced a lead candidate for further development and several good backup molecules offering a combination of excellent biophysical characteristics and thermostability properties, high affinity binding and high expression.
“Successful humanization marks an important milestone in the development of TBL-100, which we believe offers several advantages compared to other anti-tau antibodies and small molecule tau treatments in development, both in terms of safety and improved efficacy,” said Daniel G. Chain, PhD, President and CEO of TAU BIO-LOGIC. “We aim to rapidly advance this promising disease-modifying therapeutic agent for patients suffering from AD and PSP since these conditions currently lack effective therapies.
About TAU BIO-LOGIC CORPORATION
TAU BIO-LOGIC is a privately held biopharmaceutical company focused on the development of innovative high precision immunotherapies for the treatment of Alzheimer’s disease (AD), Supranuclear Palsy (PSP) and related neurodegenerative conditions. The company’s lead product is TBL-100 a monoclonal antibody that binds and inhibits the activity of C-terminally truncated tau (tauC3). The humanized antibody has an affinity of 13pM (about 100-fold higher than most marketed therapeutic antibodies have for their targets) and a specificity that is 1000-fold greater than for full length tau (FLT). The high affinity and specificity of the antibody are expected to translate into improved efficacy and safety compared to other tau antibodies currently in development.
LifeArc is a medical research charity with a 25-year legacy of helping scientists and organizations translate their research into treatments and diagnostics for patients. LifeArc turns great science into greater patient impact. The charity brings together a network of partners to tackle specific diseases and directly funds academic and early stage research. So far, LifeArc’s work has helped to develop four approved medicines (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a diagnostic test for resistance to carbapenem.
AD is the most common cause of dementia and represents an enormous and growing global public health challenge. It is a uniformly fatal neurodegenerative disorder with no cure or substantially effective treatment. AD currently affects more than 5 million Americans, 7 million Europeans and, in total, about 44 million people worldwide according to the most recent report by the Alzheimer’s Association. No disease-modifying treatments have been approved for either the early or late disease stages.
PSP is a rare and fatal degenerative neurological disorder affecting about 20,000 people in the United States. It causes progressive impairment of balance and walking; impaired eye movement, abnormal muscle tone, speech difficulties, and problems related to swallowing and eating. Affected individuals also frequently experience personality changes and cognitive impairment. Symptoms typically begin after age 60 but can begin earlier. The exact cause of PSP is unknown, and the disease is often initially misdiagnosed as Parkinson’s disease. No disease-modifying treatments have been approved for either the early or late disease stages.